TRPM8

Unraveling the Science Behind Vicks VapoRub Therapeutic Vapours

Retrieved on: 
Wednesday, September 20, 2023
Other Consumer, Research, Other Retail, Specialty, Other Health, General Health, Consumer, Health, Retail, Science, TRPA1, Inhalation, TRP, Biomedicine, Life, Eucalyptus, Employment, Cardiff University, Vicks VapoRub, Cough, Menthol, Publication, Hull York Medical School, Patient, Lower respiratory tract infection, TRPM8, Centre for Occupational and Health Psychology, Vicks, Dietary supplement, Pharmaceutical industry, Camphor

Together, these findings greatly contribute to our understanding of Vicks VapoRub’s therapeutic value as the oldest cough and cold remedy worldwide.

Key Points: 
  • Together, these findings greatly contribute to our understanding of Vicks VapoRub’s therapeutic value as the oldest cough and cold remedy worldwide.
  • In this respect a recent study revealed that a majority of consumers decide to use VapoRub in addition to their regular cold treatments.
  • 5
    Vicks VapoRub is a pharmaceutical preparation that is clinically proven to relieve congested airways.4 The success of Vicks VapoRub is based primarily on its unique composition.
  • Vicks VapoRub elevates the treatment combining powerful symptom relief through proven actives with sensorial experiences and care for the loved ones.” – Frank Kroburi, Vicks Europe Brand Director

Axalbion Presented Promising Phase 2 Clinical Data in Chronic Cough with AX-8, a Novel TRPM8 Agonist, in an Oral Presentation at the American Thoracic Society (ATS) 2023 International Conference

Retrieved on: 
Monday, May 22, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Manchester, Depression, University, Anxiety, ATS, American Thoracic Society, Cough, Chronic cough, Sleep, American Journal, International Conference on Cold Fusion, MD, Patient, Social stigma, Social isolation, TRPM8, Irritation, EudraCT, Conference, American Journal of Respiratory and Critical Care Medicine, Critical Care Medicine (journal), Urinary incontinence, Pharmaceutical industry, Poultry farming

( ClinicalTrials.gov NCT04866563 ; EudraCT Number 2021-000844-23).

Key Points: 
  • ( ClinicalTrials.gov NCT04866563 ; EudraCT Number 2021-000844-23).
  • “Refractory chronic cough is a burdensome condition that significantly impacts a patient’s quality of life, leading to urinary incontinence, social stigma, sleep disturbances, anxiety, depression and social isolation.
  • AX-8 shows promising results in this proof-of-concept study with a robust reduction in cough frequency in patients experiencing the greatest throat discomfort.
  • “We believe that AX-8 acts as a counterirritant that activates TRPM8 channels in throat sensory fibers.

Axalbion to Present Promising Phase 2 Clinical Data in Chronic Cough with AX-8, a Novel TRPM8 Agonist, in an Oral Presentation at the American Thoracic Society (ATS) 2023 International Conference

Retrieved on: 
Tuesday, March 21, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, ATS, Chronic cough, EudraCT, American Thoracic Society, International Conference of Women Engineers and Scientists, Patient, Conference, TRPM8, Cough, Pharmaceutical industry, Poultry farming

Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, announced that it will present positive results from a Phase 2 proof-of-concept study with its transient receptor potential melastatin 8 (TRPM8) agonist, AX-8, in patients with refractory or unexplained chronic cough.

Key Points: 
  • Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, announced that it will present positive results from a Phase 2 proof-of-concept study with its transient receptor potential melastatin 8 (TRPM8) agonist, AX-8, in patients with refractory or unexplained chronic cough.
  • These data will be presented in an oral session at the American Thoracic Society (ATS) 2023 International Conference, being held in Washington, DC, from May 19 - 24, 2023.
  • ( ClinicalTrials.gov NCT04866563 ; EudraCT Number 2021-000844-23).
  • Title: Randomized Proof-of-Concept Study of AX-8, a TRPM8 Agonist, in Refractory or Unexplained Chronic Cough
    Based on these positive findings, the company plans to initiate a Phase 2 study of AX-8 in chronic cough patients with moderate-to-severe throat discomfort, who are the most likely to benefit from treatment with AX-8.

Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options

Retrieved on: 
Tuesday, September 13, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Optical, Ocular hypertension, Aerie, IOP, Molecular biology, FDA, MD, Food, Glaucoma, Ophthalmology, Netarsudil, TRPM8, Aerie Pharmaceuticals, Creativity, Diabetic retinopathy, Emerging, Medicine, Review, Private Securities Litigation Reform Act, Phase 3, DME, Industry, DED, Forward-looking statement, U.S. Securities and Exchange Commission, Cornea, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, 2021 Essex County Council election, Amgen, Solution, Medication, Science, Duane syndrome, NASDAQ, Conjunctivitis, Eye, Board, Security (finance), SEC, Population and Community Development Association, KOL, Disease, Pharmaceutical industry

The event will feature Dr. Laura Periman, MD, of the Periman Eye Institute, and Dr. John Sheppard, MD, of the Virginia Eye Consultants, who will discuss New Perspectives on Dry Eye Disease (DED), including the Current Landscape, Unmet Medical Needs, and Emerging Treatment Options, including Aeries investigational TRPM8 agonist, AR-15512.

Key Points: 
  • The event will feature Dr. Laura Periman, MD, of the Periman Eye Institute, and Dr. John Sheppard, MD, of the Virginia Eye Consultants, who will discuss New Perspectives on Dry Eye Disease (DED), including the Current Landscape, Unmet Medical Needs, and Emerging Treatment Options, including Aeries investigational TRPM8 agonist, AR-15512.
  • Dr. Periman is a Cornea and Refractive Surgery Fellowship trained physician and surgeon with roots as a molecular biologist.
  • Dr. Periman is a dry eye expert who has spent years in private practices focusing on the disease, before opening and running the Periman Eye Institute.
  • He is committed to providing the highest quality eye care solutions and is widely regarded as a leader in his field.

Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease

Retrieved on: 
Monday, August 1, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Aerie Pharmaceuticals, Time, Medication, Eye, DME, Food and Drug Administration, Industry, Food, Ocular hypertension, Glaucoma, Medicine, U.S. Securities and Exchange Commission, Dry eye syndrome, SEC, Forward-looking statement, Conjunctivitis, Private Securities Litigation Reform Act, NDA, DED, Duane syndrome, COMET, TRPM8, Safety, NASDAQ, Quality of life, Medical Affairs Bureau, IOP, FDA, Security (finance), Patient, Cornea, Diabetic retinopathy, Netarsudil, Sensation, Eyelid, Aerie, Pharmaceutical industry

Aerie plans to initiate the last of the trials, the COMET-4 safety study, in the fourth quarter of 2022.

Key Points: 
  • Aerie plans to initiate the last of the trials, the COMET-4 safety study, in the fourth quarter of 2022.
  • Study participants will be randomized in a 1:1 ratio to receive either AR-15512 (0.003%) or AR-15512 vehicle as a drop dosed twice daily in each eye for three months.
  • Participants will be evaluated on multiple efficacy and safety assessments at multiple timepoints throughout the study.
  • Aerie is delighted to have enrolled the first participant in the COMET-3 study, said Michelle Senchyna, Ph.D., Head of Clinical Development and Medical Affairs at Aerie.

Axalbion Announces Positive Findings from Phase 2 Clinical Study in Chronic Cough with AX-8, a Novel TRPM8 Agonist

Retrieved on: 
Wednesday, June 29, 2022
Professional Services, Health, Venture Capital, Clinical Trials, Pharmaceutical, Biotechnology, Chronic cough, Patient, Sex, ODT, Research, Medicine, EudraCT, Duane syndrome, Population, Nobel Prize, TRPM8, Female, Mountain View, Inflammation, P2X3, GERD, BID, University, Peripheral neuropathy, Doctor of Philosophy, CA, Quality of life, Skin, Tongue, Cough, Nobel Prize in Physiology or Medicine, Safety, Asthma, Nature, MD, Pharmaceutical industry, Poultry, Physiology

Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced positive results from a Phase 2 proof-of-concept study (AX8-003) with its transient receptor potential melastatin 8 (TRPM8) agonist, AX-8, in patients with refractory or unexplained chronic cough.

Key Points: 
  • Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced positive results from a Phase 2 proof-of-concept study (AX8-003) with its transient receptor potential melastatin 8 (TRPM8) agonist, AX-8, in patients with refractory or unexplained chronic cough.
  • The Phase 2 trial was a randomized, double-blind, placebo-controlled, crossover study that evaluated the efficacy and safety of AX-8 in 51 patients with refractory or unexplained chronic cough.
  • Reduction in cough frequency was seen across patients in the study irrespective of high/low baseline cough frequency, duration of coughing, age or sex.
  • AX-8, a potent and selective transient receptor potential melastatin 8 (TRPM8) agonist, is in development for treatment of chronic cough.

Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease

Retrieved on: 
Tuesday, May 24, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Optical, Medical Affairs Bureau, Aerie, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Food, TRPM8, U.S. Securities and Exchange Commission, Dry eye syndrome, New Drug Application, Patient, NASDAQ, Quality of life, DED, Conjunctivitis, Eye, Duane syndrome, FDA, IOP, Industry, Medication, Netarsudil, Forward-looking statement, Aerie Pharmaceuticals, Ocular hypertension, Safety, Eyelid, NDA, Sensation, Diabetic retinopathy, Glaucoma, SEC, Cornea, Security (finance), DME, Pharmaceutical industry, Medical imaging

COMET-2 is the first of three trials in the Phase 3 registrational program for AR-15512.

Key Points: 
  • COMET-2 is the first of three trials in the Phase 3 registrational program for AR-15512.
  • Study participants will receive AR-15512 (0.003%) or AR-15512 vehicle as a drop dosed twice daily in each eye for three months.
  • Participants will be evaluated on multiple efficacy and safety assessments at multiple timepoints throughout the study.
  • AR-15512 has the potential to be the new standard of care for patients suffering from dry eye disease.

Axalbion Announces First Patients Treated in Phase 2 Clinical Trial in Chronic Cough with AX-8, a Novel TRPM8 Agonist

Retrieved on: 
Wednesday, October 20, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Nobel Prize, Mountain View, MD, Nobel Prize in Physiology or Medicine, CA, Chronic cough, EudraCT, Patient, ODT, Chronic obstructive pulmonary disease, Doctor of Philosophy, Skin, Disease, Peripheral neuropathy, Duane syndrome, TRPM8, Research, Cough, University, Medicine, Inflammation, GERD, Asthma, Tongue, Safety, Trial of the century, Pharmaceutical industry, Poultry, AX-8 and TRPM8, Chronic Cough, Axalbion, AX-8 AND TRPM8, CHRONIC COUGH, AXALBION

AX-8 has a novel mechanism of action targeting the TRPM8 ion channel, which may help normalize upper airway sensitivity in chronic cough patients, distinguishing it from other strategies in development.

Key Points: 
  • AX-8 has a novel mechanism of action targeting the TRPM8 ion channel, which may help normalize upper airway sensitivity in chronic cough patients, distinguishing it from other strategies in development.
  • With its safety profile and ease of administration, AX-8 has the potential to be a first-in-class drug to treat chronic cough.
  • The Phase 2 trial is a randomized, double-blind, placebo-controlled, crossover study evaluating the efficacy and safety of AX-8 in approximately 50 patients with refractory or unexplained chronic cough.
  • Axalbion is a privately held, clinical-stage biotechnology company developing novel medicines for the millions of patients who suffer from chronic respiratory disorders such as chronic cough.

Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease

Retrieved on: 
Tuesday, September 29, 2020
Biotechnology, Pharmaceutical, Optical, Health, Organ systems, Dry eye syndrome, RTT, TRPM8, Ophthalmic, Clinical medicine

AR-15512, formerly AVX-012, was acquired by Aerie in November 2019 in the acquisition of Avizorex Pharma, S.L., a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.

Key Points: 
  • AR-15512, formerly AVX-012, was acquired by Aerie in November 2019 in the acquisition of Avizorex Pharma, S.L., a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.
  • By stimulating these processes, TRPM8 agonists have the potential to restore tear film volume and reduce ocular discomfort in patients with dry eye.
  • Avizorex completed a Phase 2a study in dry eye subjects in 2019 where positive results support the therapeutic potential to treat signs and symptoms of dry eye.
  • The acceptance of the IND for AR-15512 marks the first clinical-stage dry eye product candidate for Aerie, another important milestone for the company.

Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program

Retrieved on: 
Monday, November 18, 2019
Pharmaceutical, Health, Optical, Organ systems, Dry eye syndrome, RTT, Ophthalmology, Ophthalmic, TRPM8, AVX, Avizorex Pharma, S.L., Aerie Pharmaceuticals, Inc.

(AVX Pharma or AVX), a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.

Key Points: 
  • (AVX Pharma or AVX), a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.
  • AVX completed a Phase 2a study in dry eye subjects earlier this year with its lead product candidate, AVX-012.
  • By stimulating these processes in a physiological manner, TRPM8 agonists have the potential to restore tear film stability and reduce discomfort in patients with dry eye.
  • This acquisition bolsters our pipeline with a clinical-stage dry eye product candidate, and we are excited to expand our footprint in ophthalmology.